Equibles does not estimate personal net worth.
Get an email with a short summary when Iovance Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get IOVA alertsCorleen Roche is recorded as CFO at Iovance Biotherapeutics, Inc. (IOVA). The newest filing on record that lists Corleen Roche as CFO at Iovance Biotherapeutics, Inc. (IOVA) is dated April 28, 2026. Iovance Biotherapeutics, Inc. reported in an 8-K filed August 7, 2025 that Corleen Roche was appointed Chief Financial Officer, effective August 6, 2025. Corleen Roche has spoken on 4 earnings calls and 2 other investor events across 1 company, most recently for Iovance Biotherapeutics, Inc. on September 15, 2026. Iovance Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Iovance Biotherapeutics, Inc. includes Frederick G. Vogt, Ph.D. (CEO), Frederick Vogt (CEO and General Counsel), Jean-Marc Bellemin (CFO) and 7 others.
“on August 6, 2025, Corleen Roche was appointed as Chief Financial Officer of the Company.”
“Iovance finished 2025 with positive momentum as we reported approximately 30% revenue growth with 50% margin from cost of sales in the fourth quarter. Fourth quarter product revenue of 87 million dollars demonstrated meaningful growth of approximately 30% from the prior quarter driven by Intagsy.”
“I want to demonstrate our commitment to top-line growth, operational excellence, and financial discipline as we build a sustainable, self-funded business. Second quarter total revenue was more than $99 million year-over-year and 39% sequentially from the first quarter, which have included one-time non-recurring.”
“So the short answer is no, don't expect that going forward, because we now have all of our manufacturing in-house with the ability to have continuous supply. And we achieved that through the upgrades in Q1.”
“Operational excellence, commercial growth and financial discipline drove strong top-line year-over-year growth and meaningful costs. We transformed our internal manufacturing facility to meet demand growth and scale for the future without major additional capital investment.”
“Iovance finished 2025 with positive momentum as we reported approximately 30% revenue growth with 50% margin from cost of sales in the fourth quarter. Fourth quarter product revenue of 87 million dollars demonstrated meaningful growth of approximately 30% from the prior quarter driven by Intagsy.”
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
CFO
